What is B. Riley’s Forecast for CRBP Q1 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Analysts at B. Riley issued their Q1 2025 EPS estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel anticipates that the biopharmaceutical company will post earnings per share of ($0.92) for the quarter. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($0.92) EPS and Q3 2025 earnings at ($0.92) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.24.

A number of other research analysts have also recently commented on CRBP. StockNews.com upgraded shares of Corbus Pharmaceuticals to a “sell” rating in a research report on Thursday, March 6th. Piper Sandler started coverage on shares of Corbus Pharmaceuticals in a report on Monday, December 2nd. They issued an “overweight” rating and a $35.00 target price on the stock. Jefferies Financial Group cut their target price on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday. Wedbush restated an “outperform” rating and issued a $51.00 target price on shares of Corbus Pharmaceuticals in a report on Wednesday. Finally, William Blair started coverage on shares of Corbus Pharmaceuticals in a report on Friday, February 28th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.13.

Corbus Pharmaceuticals Price Performance

Shares of NASDAQ CRBP opened at $6.42 on Friday. Corbus Pharmaceuticals has a one year low of $6.38 and a one year high of $61.90. The firm’s 50 day simple moving average is $9.56 and its two-hundred day simple moving average is $19.35. The stock has a market capitalization of $78.19 million, a P/E ratio of -1.37 and a beta of 2.63.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vestcor Inc purchased a new position in Corbus Pharmaceuticals during the third quarter valued at $64,000. JPMorgan Chase & Co. lifted its position in Corbus Pharmaceuticals by 27.0% during the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 1,172 shares during the period. MetLife Investment Management LLC purchased a new position in Corbus Pharmaceuticals during the third quarter valued at $123,000. Wells Fargo & Company MN lifted its position in Corbus Pharmaceuticals by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 2,195 shares during the period. Finally, Avanza Fonder AB purchased a new position in Corbus Pharmaceuticals during the fourth quarter valued at $84,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.